Geron sur­vives, for now, but the ju­ry at J&J is still out on the fu­ture of ime­tel­stat

Geron has sur­vived an­oth­er scrape with dis­as­ter, but it’s still op­er­at­ing un­der a dark cloud.

This morn­ing the biotech an­nounced that J&J’s re­view of the da­ta from two stud­ies of its drug ime­tel­stat war­rant­ed con­tin­ued work in myelodys­plas­tic syn­dromes and myelofi­bro­sis. But the phar­ma gi­ant $JNJ is still re­serv­ing the right to quit if the da­ta don’t hold up lat­er in the year.

That’s not a big vote of con­fi­dence.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.